Medtech Worried After UK HTA Body Moots Pharma Guidance Fees

The UK health technology assessment body, NICE, has received its first reactions from a medtech industry association to proposals to raise fees from its program of pharma guidance. If, when or how quickly the medtech sector is fully impacted is a matter of concern across the SME-based industry.

More from United Kingdom

More from Europe